Sorafenib

製品コードS7397 別名:BAY 43-9006

Sorafenib化学構造

分子量(MW):464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 24402.00
JPY 44820.00
JPY 111220.00

文献中Selleckの製品使用例(63)

カスタマーフィードバック(9)

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

  • (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
ターゲット
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外試験

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMECwNFA{ODNizszN MVPTRW5ITVJ?
MONO-MAC-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwMEC0NVgh|ryP Mny1V2FPT0WU
ALL-PO NXXVRZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEOxPFQh|ryP MkTIV2FPT0WU
NKM-1 NXXoPYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEe0NVYh|ryP NHTINYdUSU6JRWK=
CGTH-W-1 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLpTWM2OD1yLkK1NFIzKM7:TR?= NHm2UXdUSU6JRWK=
BB65-RCC MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD6S5NKSzVyPUCuOFcxPzNizszN NV\lNGx5W0GQR1XS
NOS-1 NIPpemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrLV5lPUUN3ME2wMlU3OzZizszN MXfTRW5ITVJ?
SH-4 NHO2RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPPTWM2OD1yLk[1OlE{KM7:TR?= NHjzTXpUSU6JRWK=
HOP-62 M1G5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WyXmlEPTB;MD64OVA5QCEQvF2= MXLTRW5ITVJ?
HCC2998 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;B[W8yUUN3ME2wMlg5QDF6IN88US=> NGDrTXNUSU6JRWK=
GDM-1 NHHPe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6PGlEPTB;MD65NFY6QCEQvF2= NHLLWpNUSU6JRWK=
KM12 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwMEKwPVgh|ryP MmXLV2FPT0WU
LB2518-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHxbW02UUN3ME2xMlIxQDB7IN88US=> MWHTRW5ITVJ?
NCI-H1436 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwMkG2O|gh|ryP NYfWWJF{W0GQR1XS
EM-2 NGDBU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vYZmlEPTB;MT6zOVU4QCEQvF2= MoPRV2FPT0WU
LAMA-84 NWO3UHRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwM{e2OFgh|ryP NV\6eG86W0GQR1XS
KG-1 M1jRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOyVo1[UUN3ME2xMlQ4QTN3IN88US=> MUfTRW5ITVJ?
A388 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYryVoRFUUN3ME2xMlU6OTZ3IN88US=> Mn7qV2FPT0WU
no-10 NEn4XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvoPGlbUUN3ME2xMlYyPzJ4IN88US=> MojQV2FPT0WU
SF126 NH\pXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjDdZhRUUN3ME2xMlY{QDF{IN88US=> M1LFVHNCVkeHUh?=
MEG-01 NYrnTFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rkWWlEPTB;MT64NFk5KM7:TR?= MlS4V2FPT0WU
A3-KAW NFjP[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT1TWM2OD1zLki4OFIh|ryP MUPTRW5ITVJ?
D-247MG NFPPVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvkbJdKSzVyPUKuNVQ1QCEQvF2= NXqxN2VOW0GQR1XS
OVCAR-4 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJwMkGzPVMh|ryP NGrp[4ZUSU6JRWK=
NCI-SNU-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojPTWM2OD1{LkOxOlIh|ryP NUjHfYZJW0GQR1XS
NCI-H2171 NFXOdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHezfldKSzVyPUKuN|k4PjRizszN M3vHVHNCVkeHUh?=
SIG-M5 NHvpdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\oXlRKSzVyPUKuOFIzPDJizszN M2jiUXNCVkeHUh?=
BE-13 M1[xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHSSJZKSzVyPUKuOlk3ODlizszN M2TkdHNCVkeHUh?=
K052 NUX2W44{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX6TWM2OD1{Lke0OlE3KM7:TR?= NILxTVRUSU6JRWK=
L-540 NF74XpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\qUWlEPTB;Mj63OVc5QSEQvF2= MlyyV2FPT0WU
KMOE-2 MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j0T2lEPTB;Mj64NVM2KM7:TR?= M4XDfXNCVkeHUh?=
MFH-ino MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHkd2hKSzVyPUKuPVIyQDVizszN MVLTRW5ITVJ?
HL-60 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLNTWM2OD1|LkC2Nlk6KM7:TR?= Mm[0V2FPT0WU
HCC2218 M3z1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml64TWM2OD1|LkGyNFA{KM7:TR?= MlvVV2FPT0WU
TE-5 NXLaTlFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\0TWM2OD1|LkGzNVYzKM7:TR?= MVHTRW5ITVJ?
MZ1-PC MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L1TmlEPTB;Mz60O|UxQSEQvF2= MWLTRW5ITVJ?
MRK-nu-1 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwNkG0Olgh|ryP MWPTRW5ITVJ?
MZ7-mel NYLRe2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmThTWM2OD1|Lk[2NFk6KM7:TR?= NYfBPVNlW0GQR1XS
BC-1 NGnXdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnHTWM2OD1|Lke0NFIh|ryP NGLqbW9USU6JRWK=
ST486 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHpTWM2OD1|LkizOlc{KM7:TR?= MoDJV2FPT0WU
KS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXUTWM2OD1|Lki4NVk5KM7:TR?= NEjxOmtUSU6JRWK=
SK-NEP-1 NFLtU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXzSGZKSzVyPUSuNVY5OTVizszN NYHscVZ3W0GQR1XS
BC-3 NHXpWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HlN2lEPTB;ND6yN|M6OSEQvF2= MYHTRW5ITVJ?
NCI-H1581 M1PJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTxTWM2OD12LkK4O|k5KM7:TR?= Mkj4V2FPT0WU
MHH-PREB-1 M1ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu0PGFKSzVyPUSuOFA1QDRizszN NGfXdZNUSU6JRWK=
NOMO-1 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DWSWlEPTB;ND60PFkxPSEQvF2= M4Lh[nNCVkeHUh?=
QIMR-WIL MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPlTWM2OD13LkC3Nlk1KM7:TR?= NWXxdYNRW0GQR1XS
SF539 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4SZRJUUN3ME21MlE{OjJ5IN88US=> MVPTRW5ITVJ?
TE-12 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDwTWM2OD13LkK0PVI6KM7:TR?= Mki2V2FPT0WU
NCI-H510A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTVwNEG2PFUh|ryP M2TWTHNCVkeHUh?=
JAR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fzc2lEPTB;NT61NFgzPCEQvF2= NF:wVI9USU6JRWK=
no-11 NH30bWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M171ZWlEPTB;NT63N|U3QCEQvF2= NWHOdHpYW0GQR1XS
BV-173 NEfvdo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fKb2lEPTB;NT65OVY5OiEQvF2= NVr1UlZRW0GQR1XS
SR M3z3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTZwMEC2O|gh|ryP NHzUW5VUSU6JRWK=
MOLT-16 M1vjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K1emlEPTB;Nj6yOVI3PiEQvF2= MV;TRW5ITVJ?
MZ2-MEL NWnsNmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTZwM{G4N|kh|ryP NGGyVW5USU6JRWK=
SW954 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXi2OpNFUUN3ME22MlQ2QDZ4IN88US=> MYHTRW5ITVJ?
ML-2 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvRTWM2OD14LkWyPFQ6KM7:TR?= MUPTRW5ITVJ?
OCI-AML2 M3vRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTZwNkGwOlIh|ryP NX;GcIszW0GQR1XS
SIMA MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVNnNKSzVyPUeuNFAyODFizszN MV3TRW5ITVJ?
DOHH-2 MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf4UnE3UUN3ME23MlA2Pjd4IN88US=> NHv2Z3NUSU6JRWK=
697 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1TmZKSzVyPUeuNFU6QDlizszN MmPlV2FPT0WU
NB1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{GyOWlEPTB;Nz60NFQxPyEQvF2= NV\sZ2hrW0GQR1XS
D-392MG NHi4Oo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX6RYFKSzVyPUeuOlI3PjNizszN MofLV2FPT0WU
ES8 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwN{[1NFMh|ryP M1fzPXNCVkeHUh?=
RPMI-8226 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXySW84UUN3ME23Mlg1PTFzIN88US=> NFvCfmdUSU6JRWK=
IST-MEL1 M1jSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn1eFQ1UUN3ME24MlQxODB{IN88US=> MXTTRW5ITVJ?
NB14 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO0TWM2OD16Lk[zNVM{KM7:TR?= NW[1OYh6W0GQR1XS
HD-MY-Z NYq2V3lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRThwNkO3OFYh|ryP MkK3V2FPT0WU
TE-10 M3nQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorKTWM2OD16Lke2N|U{KM7:TR?= MVXTRW5ITVJ?
LC-1F M3z6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTlwMUC4N|Qh|ryP NXLTbVJZW0GQR1XS
OS-RC-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPNI1{UUN3ME25MlEyOjR|IN88US=> MXPTRW5ITVJ?
NCI-SNU-16 NUDPO|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETQeVBKSzVyPUmuNlExOjZizszN MWPTRW5ITVJ?
SHP-77 M3HQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\zUm9mUUN3ME25MlcyPjZ{IN88US=> MYPTRW5ITVJ?
A4-Fuk NVvlRlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzuTWM2OD17Lke1OlEh|ryP NGjUc2JUSU6JRWK=
NB6 M1PPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPPZnYzUUN3ME25Mlc3ODJ7IN88US=> M4XtOHNCVkeHUh?=
JiyoyeP-2003 NGfnc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFyLkS3OFUh|ryP MVPTRW5ITVJ?
DMS-114 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFyLkW0OFEh|ryP M3vD[3NCVkeHUh?=
NB7 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFyLke1NlYh|ryP NIOxbodUSU6JRWK=
NCI-H747 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Pj[GlEPTB;MUGuNVIyPiEQvF2= M3vOVXNCVkeHUh?=
HH NHTwVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfBTWM2OD1zMT6zPFc3KM7:TR?= MYrTRW5ITVJ?
EW-18 M4H2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrxb2dKSzVyPUGxMlkxPDRizszN NUXMc5NIW0GQR1XS
CHP-126 M3rZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PkTGlEPTB;MUGuPVc{QCEQvF2= NFXYWYJUSU6JRWK=
NTERA-S-cl-D1 NVLQWYVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nCWWlEPTB;MUKuNFI4QCEQvF2= MVjTRW5ITVJ?
DEL NWTHOpZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjydJp[UUN3ME2xNk4xQTh3IN88US=> MY\TRW5ITVJ?
LU-139 M4Xxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LoV2lEPTB;MUKuOVQyOyEQvF2= MoK2V2FPT0WU
P30-OHK MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TrZmlEPTB;MUKuOVQ4QSEQvF2= MUjTRW5ITVJ?
NCI-H1522 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jhWWlEPTB;MUKuO|Q3KM7:TR?= NGPseGtUSU6JRWK=
NCI-H1299 NVO0OnZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofOTWM2OD1zMz6yPVEyKM7:TR?= NHH3[FFUSU6JRWK=
UACC-257 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmwTWM2OD1zMz61NVI3KM7:TR?= Moq5V2FPT0WU
Calu-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrwNo5KSzVyPUGzMlYxPDZizszN NH3XcnlUSU6JRWK=
NCI-H1882 M{n5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF|Lki1OVUh|ryP NVLq[IU6W0GQR1XS
BB30-HNC MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXrRXp4UUN3ME2xOE4xPjB7IN88US=> NUnqVHY5W0GQR1XS
ES1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqXYdKUUN3ME2xOE4yPTVzIN88US=> M3LLNHNCVkeHUh?=
NCI-H1694 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnziTWM2OD1zND60PFEyKM7:TR?= MkfoV2FPT0WU
IST-SL1 NXvoS|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrMTWM2OD1zND65OlE3KM7:TR?= NV7QU|JtW0GQR1XS
ECC4 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHyTHRLUUN3ME2xOU4xPTV6IN88US=> M{Do[HNCVkeHUh?=
MDA-MB-134-VI M2K1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF3LkSxN|Eh|ryP M4ntTnNCVkeHUh?=
SCH NX3mb5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF3LkS3Nlgh|ryP NYH3e4lvW0GQR1XS
SK-N-FI NHnQWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnMeo5ZUUN3ME2xOU43PTN2IN88US=> MljYV2FPT0WU
HDLM-2 NX\TO2ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfPSpBGUUN3ME2xOk4xPzF2IN88US=> NH7tcY9USU6JRWK=
Ramos-2G6-4C10 NVHnclVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxPYRKSzVyPUG2MlEzQTdizszN NHjNNlRUSU6JRWK=
EW-24 NES5OY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF4LkG2OlEh|ryP M{TqRnNCVkeHUh?=
NCI-H2141 NEjZdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u2WGlEPTB;MU[uNVg6KM7:TR?= MkLrV2FPT0WU
LC4-1 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSwTWM2OD1zNj62NVE6KM7:TR?= MUDTRW5ITVJ?
HT-144 M4LLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxW2VKSzVyPUG3MlAxPiEQvF2= M4rySnNCVkeHUh?=
SK-MEL-1 M33a[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzPT3BKSzVyPUG3MlAxPzJizszN NFzvNFVUSU6JRWK=
SCC-15 NUPVeGZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3sb21FUUN3ME2xO{4yPjN6IN88US=> MnnKV2FPT0WU
C8166 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF5Lk[4N|Mh|ryP NWDvb2N[W0GQR1XS
GOTO NHvZcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DHVWlEPTB;MUeuPFM1PCEQvF2= M174VXNCVkeHUh?=
COR-L279 NWHvXmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGcplkUUN3ME2xPE4yOzZ{IN88US=> MoOwV2FPT0WU
K-562 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfoTWM2OD1zOD63NVQ{KM7:TR?= MVzTRW5ITVJ?
ES3 NHzS[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfFUmdrUUN3ME2xPE45ODRzIN88US=> MUnTRW5ITVJ?
LU-165 NG\4PItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\PPGlEPTB;MUmuO|AxQCEQvF2= M4jKO3NCVkeHUh?=
KM-H2 NHztb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jFPGlEPTB;MkCuN|E5PCEQvF2= NUDzdnZ[W0GQR1XS
RL NV\MNIY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPiT4lKSzVyPUKwMlk3QTJizszN NVTHSodIW0GQR1XS
EW-3 M4jNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDNPHNrUUN3ME2yNU4yQDh7IN88US=> MXLTRW5ITVJ?
A101D NGWxUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPjcGpjUUN3ME2yNU4{PzV{IN88US=> MVHTRW5ITVJ?
HUTU-80 NXjkZWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnJW4ExUUN3ME2yNU4{QTR4IN88US=> NF6yZ4FUSU6JRWK=
NCI-H23 NFzBOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJzLkO5PVIh|ryP NULPR5lbW0GQR1XS
PF-382 NEDMVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezfoNZUUN3ME2yNU41PDB|IN88US=> MX\TRW5ITVJ?
LB373-MEL-D M{\BPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJzLkW2NVUh|ryP NGTJNGJUSU6JRWK=
TE-8 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvCTWM2OD1{MT62N|k1KM7:TR?= M{\u[XNCVkeHUh?=
TE-9 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Owd2lEPTB;MkGuPFUyOyEQvF2= MYnTRW5ITVJ?
Daudi NUXsXYxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPSd4dKSzVyPUKxMlk{ODRizszN NGfHPY9USU6JRWK=
D-542MG NF7JUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj6TWM2OD1{Mj6wNlU3KM7:TR?= NGXtZppUSU6JRWK=
U-698-M NH31N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHkPZZtUUN3ME2yNk41PjB|IN88US=> MlPpV2FPT0WU
ES6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfoSJM6UUN3ME2yNk44OzZ4IN88US=> MX\TRW5ITVJ?
DU-4475 NUPx[mltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ|Lki4PVch|ryP NWPV[WNQW0GQR1XS
ECC12 M1PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITONVhKSzVyPUK0MlI5ODNizszN MU\TRW5ITVJ?
C2BBe1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ2LkOyN|kh|ryP MmHjV2FPT0WU
IST-SL2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nnRWlEPTB;MkSuOFM3OiEQvF2= M3Kze3NCVkeHUh?=
DJM-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TONmlEPTB;MkSuOVIzOSEQvF2= NF3X[oNUSU6JRWK=
DMS-153 NH7XPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK3XG9KSzVyPUK0Mlg3OTRizszN M2e0[3NCVkeHUh?=
NB13 NH[zcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfoTWM2OD1{NT6wNlY2KM7:TR?= MnTUV2FPT0WU
SK-N-DZ NXXIT5lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fyeGlEPTB;Mk[uN|QyPCEQvF2= NFPSNIJUSU6JRWK=
COR-L88 NH7MWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\CTWM2OD1{Nj61O|k3KM7:TR?= NVTHXJprW0GQR1XS
LU-65 NH\lOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ4Lki1N|Uh|ryP MWLTRW5ITVJ?
TGBC1TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3oZmNKSzVyPUK2Mlk5OjhizszN M3PL[nNCVkeHUh?=
THP-1 NWH6Z3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nZXmlEPTB;MkeuNlE1OSEQvF2= NYTnRYlqW0GQR1XS
ONS-76 M2jQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLTZ3VZUUN3ME2yO{4{OzJizszN MU\TRW5ITVJ?
LC-2-ad M3XCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Ls[mlEPTB;MkeuOlI{OSEQvF2= NGPmNHlUSU6JRWK=
EW-13 NYfyWVYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXte|hSUUN3ME2yPU4yPzR4IN88US=> MmTRV2FPT0WU
MS-1 NV\RNmgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPtfXBzUUN3ME2zNE44Ojd6IN88US=> NWTWVXdsW0GQR1XS
NCI-H2227 NV3kfYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfZeHpKSzVyPUOwMlk5ODZizszN MmjmV2FPT0WU
LXF-289 NWrPNoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj4TWM2OD1|MT60OFkzKM7:TR?= M3\NWnNCVkeHUh?=
MC116 M1\NWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN{LkC4NlYh|ryP M{jCeXNCVkeHUh?=
EVSA-T M4\3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN{LkK1PFUh|ryP M16x[HNCVkeHUh?=
CTB-1 NIXuXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN|LkGxNFEh|ryP MU\TRW5ITVJ?
COLO-320-HSR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInieJZKSzVyPUOzMlE3ODNizszN NWXjcWZrW0GQR1XS
NCI-H2196 M3GwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfMUJVTUUN3ME2zN{4zPTV5IN88US=> M3m2e3NCVkeHUh?=
LB2241-RCC MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLzTWM2OD1|Mz6zNVM2KM7:TR?= NXnUW49GW0GQR1XS
LS-513 M1LyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN|Lki2N|gh|ryP NXq4dHB2W0GQR1XS
LP-1 MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLxcZdKSzVyPUOzMlk6PTZizszN NGO4UnhUSU6JRWK=
A253 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTN2LkKyPVYh|ryP NWP3fJdDW0GQR1XS
SK-MM-2 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jwbmlEPTB;M{SuPVQ2OSEQvF2= Mk\zV2FPT0WU
NCI-H1963 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf2TWM2OD1|NT6zNFczKM7:TR?= M1TxXHNCVkeHUh?=
MMAC-SF NHfyUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrTWM2OD1|NT64O|g2KM7:TR?= MYjTRW5ITVJ?
LB831-BLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTBbXpKSzVyPUO2MlA3PTRizszN NEjISlRUSU6JRWK=
WSU-NHL M37uUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW4dph{UUN3ME2zOk4yPjRizszN NV\tW5N5W0GQR1XS
CESS NFThVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4j3WGlEPTB;M{[uNlg1QCEQvF2= NILROVNUSU6JRWK=
NEC8 M4\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN4LkW4N|Uh|ryP NV;Y[GQxW0GQR1XS
KNS-42 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHsTWM2OD1|Nz6xNlM4KM7:TR?= NXPEZ|hPW0GQR1XS
MHH-CALL-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN5LkG4NlEh|ryP NXqxfY4{W0GQR1XS
K5 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LFZ2lEPTB;M{iuOFMh|ryP M{LTeHNCVkeHUh?=
CP66-MEL MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf0TWM2OD1|OT6wO|M{KM7:TR?= NFvWSIVUSU6JRWK=
OPM-2 NF;SR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTN7Lki0N|Ih|ryP NETLc4FUSU6JRWK=
IST-MES1 NVTKNlNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRyLkOwPVYh|ryP MYTTRW5ITVJ?
EC-GI-10 NFzBbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULMdpBTUUN3ME20NU42QDB3IN88US=> M3z1TXNCVkeHUh?=
CTV-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfZNWRuUUN3ME20Nk45PDB4IN88US=> NXS2dmZpW0GQR1XS
DG-75 NUK3Z2h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnJUnRXUUN3ME20N{44PTl3IN88US=> MXjTRW5ITVJ?
KNS-81-FD M4Lvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TxPWlEPTB;NEWuOFA2QCEQvF2= M2TqSnNCVkeHUh?=
NCI-H82 NVG0bXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTXTWM2OD12NT61O|U5KM7:TR?= MXrTRW5ITVJ?
RPMI-8866 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ESmZKSzVyPUS2MlE5PzNizszN MlHjV2FPT0WU
ACN NW\tUmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3KOHJKUUN3ME20Ok41OzRizszN MYnTRW5ITVJ?
NCI-H1395 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj4TXI3UUN3ME20Ok41PzV4IN88US=> M4\PT3NCVkeHUh?=
NCI-H209 Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnXUIRuUUN3ME20O{4yPDB3IN88US=> MoX4V2FPT0WU
TGW MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOxcW9sUUN3ME20PU4xPzlzIN88US=> MWrTRW5ITVJ?
NCI-H748 NVm5fGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DncmlEPTB;NEmuOFc2OyEQvF2= NFnzSFVUSU6JRWK=
EKVX MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tab2lEPTB;NEmuOlYzQCEQvF2= M1nhVXNCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
細胞試験:

[1]

+ 展開
  • 細胞株: MDA-MB-231, and HAoSMC
  • 濃度: Dissolved in DMSO, final concentrations ~10 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • 製剤: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • 投薬量: ~60 mg/kg
  • 投与方法: Orally once daily
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 63 mg/mL (135.53 mM) warming
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 400+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 464.82
化学式

C21H16ClF3N4O3

CAS No. 284461-73-0
保管
in solvent
別名 BAY 43-9006

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01751763 Completed Carcinoma Hepatocellular Bayer July 9 2013 --
NCT02530476 Active not recruiting Leukemia|Acute Myeloid Leukemia M.D. Anderson Cancer Center|Karyopharm Therapeutics Inc|National Cancer Institute (NCI) December 8 2015 Phase 1|Phase 2
NCT01258608 Completed Carcinoma Hepatocellular Human Genome Sciences Inc. a GSK Company|GlaxoSmithKline February 8 2011 Phase 2
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8 2008 Phase 1
NCT00418496 Completed Renal Cancer|Melanoma Ohio State University Comprehensive Cancer Center|Bayer|Novartis November 8 2006 Phase 1
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

Rafシグナル伝達経路

相関Raf製品

Tags: Sorafenibを買う | Sorafenib ic50 | Sorafenib供給者 | Sorafenibを購入する | Sorafenib費用 | Sorafenib生産者 | オーダーSorafenib | Sorafenib化学構造 | Sorafenib分子量 | Sorafenib代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID